Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety. Vir Biotechnology's Phase 1 trials reveal ...

More about Alterity Therapeutics Ltd. Alterity Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. Y ...

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In ...

Vir Biotechnology VIR presented encouraging safety and efficacy data in ongoing dose escalation studies for two of its dual-masked T-cell engagers (TCEs) — VIR-5818, targeting a variety of HER2 ...

The Fund seeks to replicate as closely as possible the performance of an index derived from the biotechnology segment of a U.S. total market composite index. The Fund uses a passive management ...

The Fund seeks capital appreciation by investing at least 80% of its assets in equity securities of firms engaged in research, development, distribution, and manufacture of various biotech ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

https://www.tipranks.com/news/the-fly/fortress-biotech-announces-first-patient-dosed-in-phase-2-trial-of-triplex BofA lowered the firm’s price target on Sana ...